Axsome Therapeutics (AXSM) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 351.9% versus a gain of 37.4%. Over five years, AXSM leads with a +319.8% price change compared with -60.9% for SYRE. Axsome Therapeutics is the larger company by market cap ($8.82 billion vs $7.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | SYRE |
|---|---|---|
| Share price | $168.35 | $85.69 |
| Market cap | $8.82B | $7.91B |
| 1-day change | -1.02% | +7.25% |
| YTD return | -7.82% | +143.89% |
| 1-year return | +37.41% | +351.92% |
| 5-year return | +319.83% | -60.93% |
| Forward P/E | 35.80 | — |
| EPS (TTM) | $-3.70 | $-2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $0 |
| Revenue growth (YoY) | +65.55% | — |
| Net income (latest FY) | $-183.17M | $-155.20M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | — |
| Net margin | -28.69% | — |
| 52-week high | $260.19 | $110.18 |
| 52-week low | $119.20 | $18.12 |
| Distance from 52-week high | -35.30% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.07% | +40.28% |
| Average volume | 710.84K | 1.22M |
| Shares outstanding | 52.38M | 92.29M |
| Employees | 1,346 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed AXSM by 314.5 percentage points over the past year.
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
AXSM vs SYRE FAQ
Which is bigger, Axsome Therapeutics or Spyre Therapeutics?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $8.82B compared with $7.91B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, AXSM or SYRE?
SYRE returned +351.92% over the past 12 months, compared with +37.41% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.